Literature DB >> 28720319

Safety and efficacy of anti-influenza drugs, intravenous peramivir against influenza virus infection in elderly patients with underlying disease.

Kazufumi Takamatsu1, Satoshi Marumo2, Motonari Fukui1, Atsuko Hata3.   

Abstract

We retrospectively analyzed data of 38 elderly patients, each with an underlying disease, to evaluate peramivir safety and efficacy. Six patients (15.8%) experienced adverse events, all tolerated. Median time from administration until the return to normal temperatures was 31.5 h (95% CI: 22.4-40.6). Results confirm intravenous peramivir's usefulness.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Aging; Antiviral drugs; Geriatrics; Gerontology; High-risk patient; Neuraminidase inhibitor

Mesh：

Substances：

Year:  2017        PMID： 28720319     DOI： 10.1016/j.jmii.2016.11.006

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN： 1684-1182            Impact factor:   4.399


  3 in total

1.  Effect of eleutheroside B1 on non‑coding RNAs and protein profiles of influenza A virus‑infected A549 cells.

Authors:  Wen Yan; Jing Chen; Zhenquan Wei; Xiaohu Wang; Zhiqi Zeng; Dumizulu Tembo; Yutao Wang; Xinhua Wang
Journal:  Int J Mol Med       Date:  2020-01-17       Impact factor: 4.101

2.  Inhibition effects of patchouli alcohol against influenza a virus through targeting cellular PI3K/Akt and ERK/MAPK signaling pathways.

Authors:  Yunjia Yu; Yang Zhang; Shuyao Wang; Wei Liu; Cui Hao; Wei Wang
Journal:  Virol J       Date:  2019-12-23       Impact factor: 4.099

3.  Effect of peramivir on respiratory symptom improvement in patients with influenza virus infection and pre-existing chronic respiratory disease: Findings of a randomized, open-label study.

Authors:  Motokazu Kato; Yutaka Saisho; Hiroshi Tanaka; Takuma Bando
Journal:  Influenza Other Respir Viruses       Date:  2020-07-17       Impact factor: 4.380
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.